



[REDACTED]

[REDACTED]

[REDACTED]

- 467 flu hospitalizations
- 2,685 Covid-19 hospitalizations
- 471 RSV hospitalizations (mostly children < 4 y/o)

[COVID-19 vaccination after recovery](#)

Levemir Discontinuation


Levemir will no longer be available as of mid-January. Please switch patients over to an alternative long-acting insulin ASAP.

[Levemir discontinuation notice](#)

COVID-19 Vaccinations

[COVID-19 vaccine clinic toolkit for long-term care facilities | Department of Public Health & Environment \(colorado.gov\)](#)

- The previous bivalent vaccines are no longer available in the U.S.
- Currently, the updated 2023-2024 Pfizer-BioNTech, Moderna, and Novavax Covid-19 vaccines are recommended by the CDC.
- If a person/patient has not previously received any Covid-19 vaccination, one of the aforementioned three updated 2023-2024 Covid-19 vaccines is recommended.



[Use of Updated COVID-19 Vaccines 2023–2024 Formula for Persons Aged ≥6 Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023 | MMWR \(cdc.gov\)](#)

COVID-19 Treatment Update

- Consider treatment for anyone over 50 y/o9 with high risk health condition (basically, anyone in long term care).
- Start treatment ASAP, even for mild symptoms. Must be started with 5 days of symptom onset.
- **The oral antiviral pill Paxlovid (nirmatrelvir co-packaged with ritonavir) and the IV administered drug Veklury (remdesivir) are the preferred treatments for eligible patients.**
 - I'm not sure if we can get Veklury (remdesivir) in LTC.
- [Checklist for Paxlovid prescribing from the FDA](#)




SEPTEMBER 2023

COVID-19 Outpatient Therapeutics

Clinical Decision Aid for Ages 12+ years

Adult or pediatric patients (ages 12 and older* weighing at least 40 kg) with mild to moderate COVID-19 and at high risk for progression to severe disease

* Age requirement does not apply for Veklury (remdesivir)



References:

- 1 NIH COVID-19 Treatment Guidelines: Therapeutic Management of Nonhospitalized Adults With COVID-19. <https://www.covid19treatmentguidelines.nih.gov/therapies/statement-on-therapies-for-high-risk-nonhospitalized-patients/>
- 2 Paxlovid EUA. <https://www.fda.gov/media/155050/download>
- 3 NIH's COVID-19 Treatment Guidelines Panel: Ritonavir-Boosted Nirmatrelvir (Paxlovid). <https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ritonavir-boosted-nirmatrelvir-paxlovid/>
- 4 Veklury (remdesivir) Prescribing Information. https://www.gilead.com/medialibrary/pdfs/medicines/covid-19/veklury/veklury_pi.pdf
- 5 Lagevrio EUA. <https://www.fda.gov/media/155054/download>
- 6 CDC COVID-19 Website. <https://www.cdc.gov/coronavirus/2019-ncov/index.html>
- 7 Fact Sheet for Health Care Providers: EUA of COVID-19 Convalescent Plasma for Treatment of COVID-19. <https://www.fda.gov/media/141478/download>



Paxlovid (Ritonavir/Nirmatrelvir) Drug Interactions

[Paxlovid Drug-Drug Interactions | COVID-19 Treatment Guidelines \(nih.gov\)](#)

[Checklist for Paxlovid prescribing from the FDA](#)

- There are **so many potential drug interactions** that I think it is easier to provide a list of medications that are safe to co-administer with Paxlovid.
- Use the University of Liverpool [COVID drug interaction checker](#) (or your favorite drug interaction checker) prior to giving anyone Paxlovid
- **Check Renal Function** to assess if Paxlovid can safely be given and at what dose.
 - GFR > 60: no dosage adjustment needed. Nirmatrelvir 300/ ritonavir 100mg PO BID x 5 days.
 - GFR 30-60: Nirmatrelvir 150/ ritonavir 100mg PO BID x 5 days.

**Medications Without Clinically Relevant Interactions**

These medications may be coadministered without dose adjustment and without increased monitoring. This list is not inclusive of all noninteracting medications within each drug category.

Acid Reducers

- Famotidine
- Omeprazole
- Pantoprazole

Allergy

- Cetirizine
- Diphenhydramine
- Fexofenadine
- Loratadine

Anti-Infectives

- Azithromycin
- Cidofovir
- Hydroxychloroquine
- Tecovirimat
- Valacyclovir

Cardiovascular

- Aspirin
- Atenolol
- Carvedilol
- Furosemide
- Hydrochlorothiazide
- Irbesartan
- Isosorbide dinitrate
- Lisinopril
- Losartan
- Metoprolol
- Prasugrel

Diabetes

- Empagliflozin
- Insulin
- Metformin
- Pioglitazone

Immunosuppressants

- Abrocitinib
- Baricitinib
- Methotrexate
- Mycophenolate
- Prednisone

Lipid-Modifiers

- Ezetimibe
- Pitavastatin
- Pravastatin

Migraine

- Frovatriptan
- Naratriptan
- Rizatriptan
- Sumatriptan
- Zavegepant

Neuropsychiatric

- Amitriptyline
- Bupropion
- Citalopram
- Duloxetine
- Escitalopram
- Fluoxetine
- Gabapentin
- Lorazepam
- Nortriptyline
- Olanzapine
- Paroxetine
- Sertraline
- Venlafaxine

Pain

- Acetaminophen
- Aspirin
- Codeine
- Ibuprofen
- Meloxicam
- Naproxen

Respiratory

- Corticosteroids (inhaled/nasal)
- Formoterol
- Montelukast

Miscellaneous

- Allopurinol
- Contraceptives (PO)^a
- Cyclobenzaprine
- Donepezil
- Enoxaparin
- Finasteride
- Levothyroxine
- Most mAb products^b
- Ondansetron



Influenza Vaccine Information

- [Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023–24 Influenza Season | MMWR \(cdc.gov\)](#)
- [Influenza Antiviral Medications: Summary for Clinicians | CDC](#)
- **If you are testing for COVID-19, also test for influenza.**

[flu-tx-2023Download](#)

RSV Vaccine Information


- [Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023 | MMWR \(cdc.gov\)](#)
 - A single dose RSV vaccine showed moderate-high efficacy in preventing symptomatic RSV related disease.
 - **ACIP recommends persons >60 years may receive a dose of RSV vaccine.**
 - Shared decision making emphasized.

Viral Respiratory Dz Report


- [REDACTED]
- 6.8% increase in lab positive influenza
- Influenza A (H1N1) predominant strain
- Influenza positive tests on the rise
- 11.5% positive COVID-19 test rate nationwide




2023-24 Influenza Season Week 48 ending Dec 02, 2023



Influenza Positive Tests Reported to CDC by U.S. Clinical Laboratories, National Summary, May 21, 2023 – December 2, 2023





References:

- [COVID-19 Therapeutics Decision Aid \(hhs.gov\)](https://www.hhs.gov/condition/covid-19/therapeutics)
- [COVID-19 Treatments: Key Messages for Long-Term Care Facilities \(hhs.gov\)](https://www.hhs.gov/condition/covid-19/treatments)
- [COVID-19 Treatments: Information for Long-Term Care Facilities | HHS/ASPR](https://www.hhs.gov/condition/covid-19/treatments)
- [Use of Updated COVID-19 Vaccines 2023-2024 Formula for Persons Aged \$\geq 6\$ Months: Recommendations of the Advisory Committee on Immunization Practices — United States, September 2023 | MMWR \(cdc.gov\)](https://www.cdc.gov/mmwr/preview/mmwrhtml/mm7012a1.htm)
- [COVID-19 resources for long-term and residential care facilities | Department of Public Health & Community Engagement](https://www.colorado.gov/department-of-public-health-community-engagement)



[Environment \(colorado.gov\)](https://colorado.gov)

- [Public Health Data and Analytics | El Paso County Public Health \(elpasocountyhealth.org\)](https://elpasocountyhealth.org)